淋巴瘤试验研究
我们目前正在对淋巴瘤患者进行以下研究：
The EPCORE NHL-5 Study is evaluating the safety and tolerability of a primary investigational drug in combination with other drugs for adults with non-Hodgkin lymphoma.
The EPCORE PEDS-1 Study is evaluating the safety, tolerability, pharmacokinetics (what the body does to the drug), and preliminary efficacy of an investigational drug in children, teens, and young adults with aggressive forms of mature B-cell non-Hodgkin lymphoma (NHL).
The EPCORE NHL-6 Study is evaluating the safety and efficacy of an investigational drug for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) for potential use in an outpatient (non-hospital) setting.
The EPCORE DLBCL-2 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
The EPCORE PEDS-1 Study is evaluating the safety, tolerability, pharmacokinetics (what the body does to the drug), and preliminary efficacy of an investigational drug in children, teens, and young adults with aggressive forms of mature B-cell non-Hodgkin lymphoma (NHL).
The EPCORE NHL-6 Study is evaluating the safety and efficacy of an investigational drug for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or classic follicular lymphoma (cFL) for potential use in an outpatient (non-hospital) setting.
The EPCORE FL-1 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with relapsed or refractory follicular lymphoma.
The EPCORE DLBCL-2 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
EPCORE DLBCL-4 研究正在评估一种研究药物联合一种已获批准的抗淋巴瘤药物治疗复发性或难治性弥漫性大 B 细胞淋巴瘤 (DLBCL) 成人患者的安全性和有效性，并与标准治疗进行比较。尽管该研究药物已被批准用于治疗某些 DLBCL 患者，但其在本研究中的使用被视为试验性质，因为其针对预期试验目的的安全性和有效性尚未确定。
在这些研究中评估的试验药物是一种可以与两种白细胞的蛋白结合的分子：T 细胞和 B 细胞，这两种细胞可帮助身体对抗感染。试验药物的一端结合 T 细胞的蛋白，另一端结合 B 细胞的蛋白。通过同时结合这两种细胞，试验药物可以引导 T 细胞杀死 B 细胞，包括癌变 B 细胞。从而帮助消灭非霍奇金淋巴瘤中的癌细胞。
该网站包括在美国开展的研究的相关信息。如需查看参与国家/地区的列表，请访问此页。
